Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Noninvasive drug delivery system to posterior part tissue of eye by using solid composition

A delivery system, non-invasive technology, applied in the field of non-invasive drug delivery system, can solve the problems of patients' self-use, etc., and achieve the effect of excellent mobility and convenience

Inactive Publication Date: 2008-07-30
SANTEN PHARMA CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, on the contrary, this method is a drug delivery method and a delivery technique accompanied by invasion of ocular tissues, so when administering the drug, the patient suffers from stress and pain
In addition, since the above-mentioned drug administration method cannot be used by the patient himself, it must be operated by a specialized doctor, so there is a problem in terms of convenience

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Noninvasive drug delivery system to posterior part tissue of eye by using solid composition
  • Noninvasive drug delivery system to posterior part tissue of eye by using solid composition
  • Noninvasive drug delivery system to posterior part tissue of eye by using solid composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Hydroxypropyl cellulose (hereinafter, referred to as "HPC") and carboxyvinyl polymer (hereinafter, referred to as "CVP") were weighed so that the weight ratio was 1:2, and they were pulverized and mixed uniformly in a mortar. 95 mg of this powder was weighed, fluorescein (5 mg) as a fluorescent dye was added thereto, and the mixture was pulverized and mixed in a mortar. Then, weigh 75mg of this powder, carry out compression molding (10kg / cm 2 , 10 minutes), and shaped into a disc. The prepared disc was cut into a size of 1×2 mm to obtain a HPC / CVP (1 / 2) preparation (solid composition; granular form) containing 5% (W / W) fluorescein. Hereinafter, this preparation is referred to as Test Preparation 1. In addition, Wako Pure Chemical Industries (hydroxypropyl cellulose) was used for HPC, and BASF (carboxyvinyl polymer 934P) was used for CVP.

Embodiment 2

[0078] Weigh HPC and CVP so that the weight ratio is 1:2, and grind and mix them uniformly in a mortar. 90 mg of this powder was weighed, rhodamine (10 mg) was added thereto, and the powder was further pulverized and mixed in a mortar. Then, weigh 75mg of this powder, carry out compression molding (10kg / cm 2 ; 10 minutes), shaped into discs. The fabricated disc was chopped into a size of 1×2 mm to obtain a HPC / CVP formulation (1 / 2) containing 10% (W / W) Rhodamine B (solid composition; granular). Hereinafter, this preparation is referred to as Test Preparation 2. In addition, the same thing as Example 1 was used for HPC and CVP.

Embodiment 3

[0091] Weigh HPC and CVP so that the weight ratio is 2:1, and grind and mix them uniformly in a mortar. 95 mg of this powder was weighed, fluorescein (5 mg) as a fluorescent dye was added thereto, and it was pulverized and mixed with a mortar. Then, weigh 75mg of this powder, carry out compression molding (10kg / cm 2 , 10 minutes), and shaped into a disc. The manufactured disc was cut into a size of 1×2 mm to obtain a HPC / CVP (2 / 1) preparation (solid composition; granular form) containing 5% (W / W) fluorescein. Hereinafter, this preparation is referred to as Test Preparation 3. In addition, the same thing as Example 1 was used for HPC and CVP.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a non-invasive delivery system for a drug administered, which has an excellent capability of drug transfer into the posterior eye tissue via a local eye tissue. A solid composition comprising a drug to be delivered and a mucosa-adhesive substance having an adhesion strength to the drug of 200 to 1000 g can be administered to the conjunctival sac. Thus, a drug delivery system can be constructed which has an excellent capability of drug transfer into the posterior eye tissue via a local eye tissue.

Description

technical field [0001] The present invention relates to a non-invasive drug delivery system for retina, choroid, sclera, optic nerve, tissue around optic nerve, vitreous body and other posterior ocular tissues. Background technique [0002] Among the diseases of posterior ocular tissues such as the retina, choroid, sclera, optic nerve, tissues around the optic nerve, and vitreous body, there are many intractable diseases, and many diseases show serious symptoms that can lead to blindness. Representative diseases include age-related macular degeneration, diabetic retinopathy, diabetic macular edema, uveitis, retinitis pigmentosa, proliferative vitreoretinopathy, central retinal vein occlusion, branch retinal vein occlusion, retinal Central artery occlusion, branch retinal artery occlusion, retinal detachment, cytomegalovirus retinitis, optic nerve damage associated with glaucoma, etc. The above-mentioned diseases are all diseases that cause vision loss and blindness, and the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/32A61K9/14A61K9/18A61K9/24A61K31/573A61K47/38A61P27/02
CPCA61K9/0048A61K9/0051A61K9/1635A61K9/1652A61K31/573A61K47/32A61K47/34A61K47/36A61K47/38A61P27/02A61K9/14
Inventor 冈部高明田坂文孝
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com